IcICLLe has been presented at the following meetings:
Rawstron, A; Munir, T; Muñoz-Vicente, S; Brock, K; Yates, FJ; Bishop, R; Dalal, S; de Tute, RM; Bloor, A; Sheehy, O; Pettit, A; Fox, C; Fegan, C; Devereux, S; Macdonald, D; Hillmen, P. "Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study". American Society of Haematology, 58th Annual Meeting and Exposition, December 3-6, 2016 (accepted as a poster).
Rawstron, A; Howard, D; McParland, L; de Tute, RM; Collett, L; Phillps, D; Chalmers, A; Varghese, AM; Munir, T; Gregory, WM; Bishop, R; Yates, FJ; Brock, K; Muñoz-Vicente, S; Hillmen, P. "Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up". American Society of Haematology, 58th Annual Meeting and Exposition, December 3-6, 2016 (accepted as a poster).
Talha Munir, AndyC. Rawstron, Kimone Eccleston, Surita Dalal, Ruth M. de Tute, Kristian Brock, Francesca Yates, Adrian Bloor, Christopher P. Fox, Chris Fegan, Donald Macdonald, Peter Hillmen. "The TAP IcICLLe trial assessing biological response to ibrutinib in CLL: immediate disease redistribution precedes cell cycle arrest by 2 weeks with reduced bone marrow infiltration by 6 months." 36th World Congress of the International Society of Haematology, hosted by the British Society for Haematology, Apr 2016 (accepted as a poster)
Rawstron, A; Munir, T; Dalal, S; Thompson, J; de Tute, R; Brock, K; Yates, F; Bloor, A; Fox, C; Fegan, C; MacDonald, D; Hillmen, P. “The LLR TAP IciCLLe trial assessing biological response to ibrutinib in CLL: Immediate disease redistribution precedes cell cycle arrest by 2 weeks with reduced bone marrow infiltration by 6 months." National Cancer Research Institute 2015 (accepted as poster)
Rawstron, A; Munir, T; Dalal, S; Thompson, J; Yap, C; Brock, K; Yates, F; Ogburn, E; Fox, C; MacDonald, D; Fegan, C; Bloor, A; Hillmen, P. “The LLR TAP IciCLLe trial assessing biological response to ibrutinib in CLL: Immediate disease redistribution precedes cell cycle arrest by 2 weeks with reduced bone marrow infiltration by 6 months." European Haematology Association 2015, Abstr. 4163 (accepted as oral presentation).
Rawstron, A; Munir, T; Eccleston, K; Dalal, S; de Tute, RM; Brock, K; Yates, F; Bloor, A; Fox, C; Fegan, C; Macdonald, D; Hillmen, P. “The LLR TAP IciCLLe Trial: Detailed assessment of the response to Ibrutinib provides insights into the mode of action and pattern of response in treatment naïve and refractory CLL”. XVI International Workshop on CLL 2015 (accepted as poster).